STAB — Statera Biopharma Share Price
Last trade - 00:00- $0.01m
- $5.97m
- $1.49m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | -287.51% | ||
| Operating Margin | -2363.75% | ||
Financial Summary
| Year End 31st Dec | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1.95 | 1.14 | 1.11 | 0.26 | 1.49 | n/a | n/a | -15.82% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Statera Biopharma, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body’s immune system and restore homeostasis. Through its developmental Advanced Immunomodulating Multi-Component System (AIMS) platform, it has advanced several late-stage developmental product candidates. AIMS allows it to integrate multiple factors that define a superior composition, including key pharmacokinetic-pharmacodynamic relationships, potency, and selectivity. The Company has a platform of toll-like receptor (TLR) agonists with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and Entalasta. It has clinical and preclinical programs for Crohn’s disease (STAT-201), hematology (Entolimod) and inflammation (STAT-300) in addition to potential expansion into fibromyalgia and multiple sclerosis.
Directors
- Lea Verny NEC (55)
- Michael Handley PRE (50)
- Peter Aronstam CFO (68)
- Taunia Markvicka COO (52)
- Robert Buckheit CTO (60)
- Christopher Zosh VFN (45)
- Cozette Mcavoy OTH (41)
- Clifford Selsky OTH (72)
- Steve Barbarick DRC
- Randy Saluck IND (55)
- Last Annual
- December 31st, 2021
- Last Interim
- September 30th, 2022
- Incorporated
- June 5th, 2003
- Public Since
- July 21st, 2006
- No. of Employees
- 46
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 71,416,038
- Address
- 2537 Research Boulevard, Suite 201, FORT COLLINS, 80526
- Web
- https://www.staterabiopharma.com/
- Phone
- +1 7168496810
- Contact
- Nichol Ochsner
- Auditors
- BF Borgers CPA PC
Upcoming Events for STAB
Similar to STAB
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
As of Today at 23:26 UTC, shares in Statera Biopharma are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Statera Biopharma last closed at $0.00 and the price had moved by -85.71% over the past 365 days. In terms of relative price strength the Statera Biopharma share price has underperformed the S&P500 Index by -86.75% over the past year.
There is no consensus recommendation for this security.
Find out moreStatera Biopharma does not currently pay a dividend.
Statera Biopharma does not currently pay a dividend.
Statera Biopharma does not currently pay a dividend.
To buy shares in Statera Biopharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Statera Biopharma had a market capitalisation of $0.01m.
Here are the trading details for Statera Biopharma:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: STAB
Based on an overall assessment of its quality, value and momentum Statera Biopharma is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Statera Biopharma. Over the past six months, its share price has underperformed the S&P500 Index by -66.58%.
As of the last closing price of $0.00, shares in Statera Biopharma were trading -69.28% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Statera Biopharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Statera Biopharma's management team is headed by:
- Lea Verny - NEC
- Michael Handley - PRE
- Peter Aronstam - CFO
- Taunia Markvicka - COO
- Robert Buckheit - CTO
- Christopher Zosh - VFN
- Cozette Mcavoy - OTH
- Clifford Selsky - OTH
- Steve Barbarick - DRC
- Randy Saluck - IND